Return to homepagePandemic Pact

to accelerate the early clinical development of novel SARS-CoV-2 Mpro antiviral drug

Grant number: INV-037900

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    2021

  • Known Financial Commitments (USD)

    $6,500,000

  • Funder

    Gates Foundation

  • Principal Investigator

    N/A

  • Research Location

    United States of America

  • Lead Research Institution

    Calibr, a division of The Scripps Research Institute

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Therapeutics logistics and supply chains and distribution strategies

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

N/A